ReachMD

Announcer Intro:
You’re listening to NeuroFrontiers on ReachMD. Today, the President of the European Committee for Treatment and Research in Multiple Sclerosis, also known as ECTRIMS, Dr. Mar Tintoré, will give us an overview of what to expect from the presentation on diagnostic criteria for multiple sclerosis, or MS, patients. She also serves as the Clinical Coordinator of the Multiple Sclerosis Centre of Catalonia Cemcat at the Hospital Vall d’Hebron in Barcelona, Spain. Here’s Dr. Tintoré now.

Dr. Tintoré:
So in this ECTRIMS meeting, we are going to finally listen to the update of the new diagnostic criteria. Professor Montalban is going to present this new criteria in which many interesting things are going to happen. We are probably going to be able to diagnose the disease even earlier, even before the clinical symptoms happen. We are probably going to also be able to use more biomarkers to identify the disease. And maybe also, we will have the possibility to use different MRI techniques in those cases that are more challenging and in which we have more doubts. So I think we are going to listen to many important, interesting changes that are going to challenge us that are going to also be very helpful for our patients, and they are going to give us opportunities for even earlier diagnosis, and therefore also, earlier treatments, et cetera. Important to mention that these criteria have been developed with a specific interest in trying to be global. So taking also into consideration diversity, different settings, different tools that can be useful in different settings and in different countries, etc. So this is an important thing. And also, in terms of the people who collaborate to develop the diagnostic criteria.

Announcer Outro:
That was Dr. Mar Tintoré talking about diagnostic criteria for MS. To access this and other  episodes in our series, visit NeuroFrontiers on ReachMD.com, where you can Be Part of the  Knowledge. Thanks for listening!